114 related articles for article (PubMed ID: 9192909)
1. Reduction of chronic ciclosporin nephrotoxicity by thromboxane synthase inhibition with OKY-046.
Kim YJ; Park YH; Moon HK
Kidney Blood Press Res; 1997; 20(1):38-43. PubMed ID: 9192909
[TBL] [Abstract][Full Text] [Related]
2. The reversal of experimental cyclosporin A nephrotoxicity by thromboxane synthetase inhibition.
Grieve EM; Hawksworth GM; Simpson JG; Whiting PH
Biochem Pharmacol; 1993 Mar; 45(6):1351-4. PubMed ID: 8466554
[TBL] [Abstract][Full Text] [Related]
3. Modulation of experimental cyclosporine nephrotoxicity by inhibition of thromboxane synthesis.
Petric R; Freeman D; Wallace C; McDonald J; Stiller C; Keown P
Transplantation; 1990 Oct; 50(4):558-63. PubMed ID: 2219273
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the thromboxane A2 synthetase inhibitor OKY-046 in a warm ischemia-reperfusion rat model.
Garvin PJ; Niehoff ML; Robinson SM; Heisler T; Salinas-Madrigal L; Contis J; Solomon H
Transplantation; 1996 May; 61(10):1429-34. PubMed ID: 8633364
[TBL] [Abstract][Full Text] [Related]
5. Chronic thromboxane inhibition preserves function of rejecting rat renal allografts.
Coffman TM; Ruiz P; Sanfilippo F; Klotman PE
Kidney Int; 1989 Jan; 35(1):24-30. PubMed ID: 2651752
[TBL] [Abstract][Full Text] [Related]
6. The combined use of prostaglandin I2 analogue (OP-2507) and thromboxane A2 synthetase inhibitor (OKY-046) strongly inhibits atherosclerosis of aortic allografts in rats.
Hirano T; Nakafusa Y; Kawano R; Motoyama K; Arima T; Sugitani A; Tanaka M
Surgery; 2001 May; 129(5):595-605. PubMed ID: 11331452
[TBL] [Abstract][Full Text] [Related]
7. Prevention of experimental cyclosporine nephrotoxicity by dietary supplementation with LSL 90202, a lysine salt of eicosapentaenoic acid. Role of thromboxane and prostacyclin in renal tissue.
Torras J; Valles J; Sanchez J; Sabate I; Seron D; Carrera M; Castelao AM; Herrero I; Puig-Parellada P; Alsina J
Nephron; 1994; 67(1):66-72. PubMed ID: 8052370
[TBL] [Abstract][Full Text] [Related]
8. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity.
Smith SR; Kubacki VB; Rakhit A; Martin LL; Schaffer AV; Jasani MK; Hefty DJ; Johnston T; Cannon C; Bennett WM
Transplantation; 1993 Dec; 56(6):1422-6. PubMed ID: 8279014
[TBL] [Abstract][Full Text] [Related]
9. Effect of thromboxane synthetase inhibition and angiotensin converting enzyme inhibition on acute cyclosporin A nephrotoxicity.
Grieve EM; Hawksworth GM; Simpson JG; Whiting PH
Biochem Pharmacol; 1990 Nov; 40(10):2323-9. PubMed ID: 2244933
[TBL] [Abstract][Full Text] [Related]
10. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
[TBL] [Abstract][Full Text] [Related]
11. Selective thromboxane A2 synthase inhibition by OKY-046 prevents cardiopulmonary dysfunction after ovine smoke inhalation injury.
Westphal M; Noshima S; Isago T; Fujioka K; Maybauer MO; Maybauer DM; Traber LD; Flynn JT; Westphal-Varghese BB; Traber DL
Anesthesiology; 2005 May; 102(5):954-61. PubMed ID: 15851882
[TBL] [Abstract][Full Text] [Related]
12. Effects of OKY-046 and nifedipine in cyclosporine-induced renal dysfunction in rats.
Papanikolaou N; Darlametsos I; Tsipas G; Morphake P; Bokas S; Gkikas G; Hornych A; Bariety J; Gkika EL; Karageorgou I; Patsialos K
Prostaglandins Leukot Essent Fatty Acids; 1996 Oct; 55(4):249-56. PubMed ID: 8951993
[TBL] [Abstract][Full Text] [Related]
13. Effects of OKY 046, a thromboxane-synthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites.
Gentilini P; Laffi G; Meacci E; La Villa G; Cominelli F; Pinzani M; Buzzelli G
Gastroenterology; 1988 Jun; 94(6):1470-7. PubMed ID: 3360268
[TBL] [Abstract][Full Text] [Related]
14. Effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity.
Smith SR; Creech EA; Schaffer AV; Martin LL; Rakhit A; Douglas FL; Klotman PE; Coffman TM
Kidney Int; 1992 Jan; 41(1):199-205. PubMed ID: 1593856
[TBL] [Abstract][Full Text] [Related]
15. Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy.
Hora K; Oguchi H; Furukawa T; Hora K; Tokunaga S
Nephron; 1990; 56(3):297-305. PubMed ID: 2077412
[TBL] [Abstract][Full Text] [Related]
16. A high plasma prostaglandin to thromboxane ratio protects against renal ischemia.
Kaufman RP; Anner H; Kobzik L; Valeri CR; Shepro D; Hechtman HB
Surg Gynecol Obstet; 1987 Nov; 165(5):404-9. PubMed ID: 3672299
[TBL] [Abstract][Full Text] [Related]
17. Renal effects of the inhibitor of thromboxane A2-synthetase OKY-046.
Hatziantoniou C; Papanikolaou N
Experientia; 1986 Jun; 42(6):613-5. PubMed ID: 3522267
[TBL] [Abstract][Full Text] [Related]
18. Role of thromboxane A2 in the hypotensive effect of captopril in essential hypertension.
Kudo K; Abe K; Chiba S; Sato M; Yasujima M; Kohzuki M; Omata K; Tanno M; Tsunoda K; Yoshinaga K
Hypertension; 1988 Feb; 11(2):147-52. PubMed ID: 3277911
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of thromboxane synthetase inhibitor on hypertensive renal damage in Dahl salt-sensitive rats.
Gomi T; Ikeda T; Sasaki Y; Kosugi T; Shibuya Y; Sakurai J
Clin Exp Pharmacol Physiol Suppl; 1995 Dec; 22(1):S371-3. PubMed ID: 9072433
[TBL] [Abstract][Full Text] [Related]
20. [The effects of thromboxane A2 synthetase inhibitor on chronic rejection of kidney transplantation].
Imanishi M; Ikegami M; Nishioka T; Ishii T; Uemura T; Kunikata S; Kanda H; Matsuura T; Akiyama T; Kurita T
Nihon Hinyokika Gakkai Zasshi; 1990 Jun; 81(6):895-901. PubMed ID: 2402113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
